Skip to main content
Log in

Pharmaceutical marketing has real and proven value

Characteristics of materials distributed by drug companies: Four points of view

  • Editorials
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Stryer D, Bero LA. Characteristics of materials distributed by drug companies: an evaluation of appropriateness. J Gen Intern Med. 1996;11:575–83.

    PubMed  CAS  Google Scholar 

  2. Yasuda SU, Woosley RL. The clinical value of FDA class C drugs approved from 1981–1988. Clin Pharmacol Ther. 1992;52:577–82.

    Article  PubMed  CAS  Google Scholar 

  3. Suresh CG, Greene D, Coupe MO. Use of adenosine and effectiveness of pharmaceutical marketing. Lancet. 1993;341:1540.

    Google Scholar 

  4. Beckwith C, Munger MA. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction. Ann Pharmacother. 1993;27:755–66.

    PubMed  CAS  Google Scholar 

  5. Peltzman S. The diffusion of pharmaceutical innovation. In: Peltzman S, Helms RB, eds. Drug Development and Marketing. Washington, DC: AEI Center for Health Policy Research; 1975.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beary, J.F. Pharmaceutical marketing has real and proven value. J Gen Intern Med 11, 635–636 (1996). https://doi.org/10.1007/BF02599032

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02599032

Navigation